Arcus Biosciences

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arcus Biosciences reports strong Q3 performance with promising trial results

Arcus Biosciences delivered strong financial performance and promising clinical trial results in Q3 2023.
The company faces financial challenges amidst high R&D expenses but maintains a solid cash position and operational strength.
Strategic opportunities exist in advancing differentiated therapies, navigating competitive landscapes, and exploring combination treatments.
Successfully addressing challenges and capitalizing on opportunities can drive growth and market success for Arcus Biosciences.

Arcus Biosciences excels in Q4, poised for oncology innovation

Arcus Biosciences reported strong financials, positive program results, and strategic partnerships, positioning the company for continued growth and innovation in oncology.
Operational changes reflect a proactive approach to portfolio optimization and trial advancement, demonstrating Arcus's commitment to maximizing program potential and patient impact.
Challenges in data interpretation, program comparisons, and trial planning require careful navigation, while upcoming opportunities in 2024 offer avenues for showcasing progress and driving future success.
With a focus on expanding patient cohorts, optimizing doses, and revealing trial designs, Arcus is poised to capitalize on opportunities, address challenges, and deliver value to stakeholders.

Arcus Biosciences reports robust Q1 results and advances promising pipeline

Arcus Biosciences showcased strong financials, positive study data, and strategic partnerships, positioning them well for future growth and innovation.
While facing challenges in managing expenses and differentiation strategies, the company is actively exploring opportunities in combination therapies and tumor targeting.
The emphasis on good data, strategic planning, and leveraging biological insights highlights Arcus Biosciences' commitment to advancing drug development efforts and improving patient outcomes.

Arcus Biosciences reports promising clinical results and solid financials

Arcus Biosciences demonstrated strong clinical progress with casdatifan and domvanalimab, supported by solid financial performance. While challenges in clinical trial execution and market competition exist, the company is well-positioned to capitalize on opportunities for growth through upcoming Phase 3 studies and data presentations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arch Resources

Suzano S.A. - ADR

Arcus Biosciences (RCUS), Suzano (SUZ), and Arch Resources (ARCH) has been selected as the top picks with a high net income ratio.

Buy 3 Top Profitable Stocks Using Net Income Ratio

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate at the following upcoming February 2023 virtual investor events

Arcus Biosciences to Participate at Upcoming Virtual Investor Events

The heavy selling pressure might have exhausted for Arcus Biosciences, Inc. (RCUS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -45.21% in 4 Weeks, Here's Why Arcus Biosciences, Inc. (RCUS) Looks Ripe for a Turnaround

Gilead Sciences

Arcus Biosciences Inc and Gilead Sciences Inc shares have both taken a tumble after the companies reported positive but not groundbreaking results from a Phase 2 trial involving its new lung cancer drug combinations.   The results showed the program is viable but left investors questioning how the pair and their proposed therapeutic could compete against other more established companies in the tough research and development space.

Arcus Biosciences, Gilead Sciences shares fall as new lung cancer drug data fails to meet investor expectations

Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. RCUS stock skidded more than 20%.

Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche

Shares of Arcus Biosciences Inc. RCUS, -1.23% were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatment for metastatic non-small cell lung cancer that it's developing with Gilead Sciences Inc. GILD, -0.39% improved progression-free survival and overall response rate [ORR] in a Phase 2 clinical study. "The data clearly show that the program is viable, keeping hope alive for active building blocks within the large lung cancer space, but numerical ORR may be disappointing to some and it remains to be seen how much GILD/RCUS's combo can truly differentiate vs.

Arcus Biosciences, Gilead shares are down after sharing data about new lung cancer drug

FOSTER CITY, Calif., & HAYWARD, Calif.--( BUSINESS WIRE )--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced positive results from the fourth interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations. ARC-7 is a Phase 2, multicenter, three-arm, randomized, open-label study evaluating the combinations of Fc-silent anti-TIGIT monoclonal antibody domvanalimab plus anti-PD1 monoclonal antibody zimberelimab (doublet) and domvanalimab plus zimberelimab and etrumadenant, an A2a/b adenosine receptor antagonist (triplet), versus zimberelimab monotherapy. These results will be presented tomorrow during the American Society of Clinical Oncology (ASCO) Monthly Plenary Series, a new, virtual forum for presentation and discussion of the latest cancer research.

Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study

The consensus price target hints at a 44.5% upside potential for Arcus Biosciences, Inc. (RCUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Arcus Biosciences, Inc. (RCUS) Could Rally 45%: Here's is How to Trade

Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher. The post Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges appeared first on Investor's Business Daily.

Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges

FOSTER CITY, Calif. & HAYWARD, Calif.--( BUSINESS WIRE )--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) today announced a positive update from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations. ARC-7 is evaluating the combinations of anti-TIGIT antibody domvanalimab plus anti-PD-1 antibody zimberelimab (doublet), and domvanalimab plus zimberelimab and etrumadenant, an A2a/b adenosine receptor antagonist (triplet), versus zimberelimab alone, and represents the first randomized Phase 2 study of an Fc-silent anti-TIGIT/anti-PD-1 combination. The protocol-specified fourth interim analysis was conducted when the trial reached full enrollment, with a clinical data cutoff date of August 31, 2022. A total of 150 patients have been randomized across the three study arms.

Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer

Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer

HAYWARD, Calif.--( BUSINESS WIRE )--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a virtual fireside chat at the upcoming 5th Annual Evercore ISI HealthCONx Conference. The fireside chat will take place on Wednesday, November 30th, 2022 at 11:20 a.m. Eastern Time.

Arcus Biosciences to Participate in the 5th Annual Evercore ISI HealthCONx Conference

The consensus price target hints at a 75% upside potential for Arcus Biosciences, Inc. (RCUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 75% Upside in Arcus Biosciences, Inc. (RCUS): Can the Stock Really Move This High?

Chimerix

Vista Oil & Gas SAB de CV

Chimerix (CMRX), Vista Oil & Gas (VIST) and Arcus Biosciences (RCUS) have been selected as the top picks with a high net income ratio.

Buy 3 of the Best Stocks by Using Net Income Ratio

Arcus Biosciences Reports Third Quarter 2022 Financial Results and Provides a Pipeline Update

The consensus price target hints at a 74.8% upside potential for Arcus Biosciences, Inc. (RCUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Arcus Biosciences, Inc. (RCUS) Climb 75% to Reach the Level Wall Street Analysts Expect?

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Dimitry S.A. Nuyten, M.D., Ph.D has been appointed chief medical officer (CMO) effective August 1, 2022. In his role as CMO, Dr. Nuyten will oversee Arcus's clinical development organization that includes nearly 200 employees and six clinical-stage programs t

Arcus Biosciences Appoints Dimitry Nuyten, M.D., Ph.D. as Chief Medical Officer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the second quarter ended June 30, 2022 and provided a pipeline update on its six clinical-stage molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b), HIF-2a and PD-1 – across multiple common cancers. Arcus and Gilead continue to

Arcus Biosciences Reports Second Quarter 2022 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a virtual fireside chat at the upcoming 13th Annual Wedbush PacGrow Healthcare Conference. The fireside chat will take place on Wednesday, August 10th, 2022 at 12:00 p.m. ET. A live webcast of the fireside chat will be available by

Arcus Biosciences to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 43rd Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, California. The fireside chat will take place on Thursday, June 16th, 2022 at 9:20 a.m. PT. A liv

Arcus Biosciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -215.66% and 88.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the first quarter ended March 31, 2022 and provided a pipeline update on its six clinical-stage molecules targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a and PD-1 across multiple common cancers. In addition, today

Arcus Biosciences Reports First Quarter 2022 Financial Results and Provides a Pipeline Update, Including from the Third Interim Analysis for the ARC-7 Study

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced it will report financial results and key pipeline updates for the first quarter ended March 31, 2022 after the U.S. markets close on Monday, May 9, 2022. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing different

Arcus Biosciences to Report First Quarter 2022 Financial Results and Pipeline Update

Beam Therapeutics

BioNTech SE

Vir Biotechnology

These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns.

4 Undervalued Biotech Stocks to Add to Your Buy List

Shares of Arcus Biosciences Inc. RCUS, +9.07% gained 13.1% in premarket trading on Tuesday after the company said it is set to join the S&P SmallCap 600 SML, -0.38% before the market opens on Thursday. Arcus shares are down 13.8% so far this year, while the SmallCap 600 is down 5.0% and the broader S&P 500 SPX, +0.81% has declined 3.8%.

News for Arcus Biosciences Stock (RCUS)